Chemical inhibitors of C12orf43 can interfere with its function through various biochemical pathways. Wortmannin and LY294002 are both inhibitors of phosphoinositide 3-kinases (PI3K), a family of enzymes involved in cellular functions such as growth, proliferation, differentiation, motility, and survival. By inhibiting PI3K, these chemicals can disrupt the PI3K/AKT pathway, which is implicated in a multitude of cellular processes. This disruption could lead to the functional inhibition of C12orf43 if it is regulated by or dependent on signals from this pathway. Another broad-spectrum inhibitor, Staurosporine, targets a wide range of kinases, which may include those that phosphorylate C12orf43 or regulate its activity, leading to a decrease in its functional activity. Similarly, Rapamycin's inhibition of the mTOR pathway could result in diminished C12orf43 activity by affecting downstream processes that it regulates.
Further down the signaling cascade, SB203580 and U0126 target the MAPK pathway at different points: SB203580 inhibits p38 MAPK, while U0126 inhibits MEK1/2, two kinases that are upstream of ERK. This could lead to reduced signaling to proteins that interact with C12orf43, thereby inhibiting its function. PD98059, another MEK inhibitor, can similarly disrupt the MAPK/ERK pathway and result in the inhibition of C12orf43 by interfering with the signaling processes it is involved in. SP600125, which inhibits JNK, can decrease the phosphorylation of transcription factors potentially involved in the regulation of genes that interact with C12orf43, leading to its inhibition. PP2, an Src family kinase inhibitor, can reduce activity in downstream signaling pathways that involve C12orf43, thereby leading to a reduction in its activity. Dasatinib and Sorafenib, by inhibiting Bcr-Abl and Src family kinases and multiple receptor tyrosine kinases respectively, can result in the inhibition of C12orf43 by preventing the phosphorylation of substrates that regulate its function. Lastly, Sunitinib, with its multi-targeted receptor tyrosine kinase inhibitory activity, can disrupt signaling pathways that involve C12orf43, leading to the inhibition of the protein's functional activities within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases (PI3K), which could lead to the inhibition of C12orf43 by affecting the PI3K/AKT pathway that is involved in various cellular processes, including those potentially regulated by C12orf43. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor that can inhibit the PI3K/AKT signaling pathway, which is crucial for many cellular functions and possibly the activity of C12orf43. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent kinase inhibitor, known to inhibit a broad range of kinases. It can inhibit kinases that may phosphorylate C12orf43 or regulate its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a part of the mTOR signaling pathway. Inhibition of this pathway can lead to functional inhibition of C12orf43 by affecting downstream processes regulated by mTOR that involve C12orf43. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, and by inhibiting this kinase, it can reduce the phosphorylation of proteins that potentially interact with C12orf43, leading to its inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, which are upstream of ERK in the MAPK pathway, potentially leading to reduced signaling to proteins that interact with C12orf43, thus inhibiting its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is another MEK inhibitor that can block the MAPK/ERK pathway, potentially leading to the inhibition of C12orf43 by impairing signaling processes that involve C12orf43. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which can decrease the phosphorylation of transcription factors that regulate genes interacting with C12orf43, potentially leading to the inhibition of C12orf43. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor that can reduce the activity of downstream signaling pathways that involve C12orf43, leading to its inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib inhibits Bcr-Abl and Src family kinases. By inhibiting these kinases, it can reduce phosphorylation of substrates that regulate C12orf43, thereby inhibiting its function. |